Kimelman & Baird LLC held its stake in shares of Celgene Co. (NASDAQ:CELG) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,700 shares of the biopharmaceutical company’s stock at the close of the second quarter. Kimelman & Baird LLC’s holdings in Celgene were worth $351,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Capital Counsel LLC NY boosted its position in shares of Celgene by 0.4% during the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC boosted its position in shares of Celgene by 0.6% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 11 shares in the last quarter. Sowell Financial Services LLC boosted its position in shares of Celgene by 0.5% during the 1st quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 13 shares in the last quarter. South Texas Money Management Ltd. boosted its position in shares of Celgene by 0.6% during the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 15 shares in the last quarter. Finally, Flagship Harbor Advisors LLC boosted its position in shares of Celgene by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 18 shares in the last quarter. 80.16% of the stock is currently owned by institutional investors.

In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.95% of the stock is currently owned by company insiders.

CELG has been the topic of several analyst reports. BMO Capital Markets increased their price target on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Oppenheimer restated a “buy” rating and issued a $170.00 target price on shares of Celgene in a research report on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price on the stock in a research report on Monday, October 23rd. Cann restated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. Celgene presently has an average rating of “Buy” and an average price target of $136.21.

Celgene Co. (CELG) opened at $108.24 on Friday. The stock has a market cap of $85,849.04, a price-to-earnings ratio of 17.04, a PEG ratio of 0.84 and a beta of 1.78. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.58 earnings per share. sell-side analysts forecast that Celgene Co. will post 6.67 EPS for the current fiscal year.

WARNING: “Kimelman & Baird LLC Holds Position in Celgene Co. (CELG)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/kimelman-baird-llc-holds-position-in-celgene-co-celg/1764859.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.